We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Three Firms Guide Catalent's $140M Pharma Biz Buy

Law360 (July 3, 2018, 6:22 PM EDT) -- Drug development and delivery company Catalent Inc. said on Tuesday that it has agreed to acquire Juniper Pharmaceuticals Inc. in a deal that carries an equity value of approximately $139.6 million on a fully diluted basis and was guided by Goodwin Procter LLP.

Catalent will acquire all of the outstanding shares of Juniper for $11.50 per share, which is a 59.7 percent premium on the company’s share price as Jan. 30, 2018, when it announced it would seek strategic alternatives. The transaction is subject to customary closing conditions and is expected to be completed in the third quarter of 2018....

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS